Solid Biosciences Inc. (SLDB): Total Assets
$232.54M
As of 2025-12-31
$420.58M
As of 2026-06-30
-3.7%
3-year compound annual growth
+6.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $232.54M | +23.3% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $188.66M | +14.4% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $164.94M | -36.6% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $260.25M | +12.0% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $232.38M | +35.8% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $171.17M | +65.4% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $103.47M | -25.9% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $139.60M | +83.2% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $76.19M | n/a | 2019-03-13, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $232.54M | +23.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $228.79M | -38.4% |
| Agenus Inc (AGEN) | 2025-12-31 | $226.80M | +0.2% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $223.70M | -36.7% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $221.47M | -28.8% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $221.10M | -31.9% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $245.96M | -13.0% |
Compare SLDB, DBVT, TCRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗